Drug intelligence / Profile preview

AKB-10108

Development stage: Preclinical
Lead developer: Akebia Therapeutics
Modality: Small Molecules
Administration: Subcutaneous

Overview

AKB-10108 is a drug under development by Akebia Therapeutics, Inc. It is targeted for the treatment of **Bronchopulmonary Dysplasia** and **Retinopathy of Prematurity**, both conditions affecting neonates. The drug is currently in the **preclinical** phase. Details about its mechanism of action are not explicitly mentioned in the available data, but given Akebia's focus on HIF (hypoxia-inducible factor) pathways, it may involve similar pathways as other drugs developed by the company, such as vadadustat, which targets anemia in chronic kidney disease.

Targets

PHD1 (Prolyl hydroxylase domain-containing protein 1)

Beyond the preview

Go deeper on AKB-10108.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AKB-10108.

Explore the full profile